Literature DB >> 29472055

Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung Cancer.

Jang Ho Cho1, Jong-Mu Sun1, Se-Hoon Lee1, Jin Seok Ahn1, Keunchil Park1, Myung-Ju Ahn2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29472055     DOI： 10.1016/j.jtho.2017.10.007

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  9 in total

Review 1.  Abdominal CT manifestations of adverse events to immunotherapy: a primer for radiologists.

Authors:  Ali Pourvaziri; Anushri Parakh; Pierpaolo Biondetti; Dushyant Sahani; Avinash Kambadakone
Journal:  Abdom Radiol (NY)       Date:  2020-09

2.  Hepatobiliary and Pancreatic Adverse Events.

Authors:  Hao Chi Zhang; Lan Sun Wang; Ethan Miller
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  Clinical Characteristics of ICI-Related Pancreatitis and Cholangitis Including Radiographic and Endoscopic Findings.

Authors:  Ryota Nakano; Hideyuki Shiomi; Aoi Fujiwara; Kohei Yoshihara; Ryota Yoshioka; Shoki Kawata; Shogo Ota; Yukihisa Yuri; Tomoyuki Takashima; Nobuhiro Aizawa; Naoto Ikeda; Takashi Nishimura; Hirayuki Enomoto; Hiroko Iijima
Journal:  Healthcare (Basel)       Date:  2022-04-20

Review 4.  Hepatotoxicity Induced by Biological Agents: Clinical Features and Current Controversies.

Authors:  Nelia Hernandez; Fernando Bessone
Journal:  J Clin Transl Hepatol       Date:  2022-01-25

5.  Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management.

Authors:  Borui Pi; Jin Wang; Yifan Tong; Qiao Yang; Fangfang Lv; Yunsong Yu
Journal:  Eur J Gastroenterol Hepatol       Date:  2021-12-01       Impact factor: 2.586

Review 6.  Gastrointestinal adverse events of immunotherapy.

Authors:  Giovanni Cappello; Francesca Molea; Delia Campanella; Francesca Galioto; Filippo Russo; Daniele Regge
Journal:  BJR Open       Date:  2021-10-20

7.  Checkpoint Inhibitor in a Melanoma Patient With Polyendocrinopathy and Gangrenous Gallbladder With a Mass.

Authors:  Nayson L Fernandes; Soujanya Sodavarapu; Sukhmine Nedopil; Nikita Mohapatra; Dinesh Vyas
Journal:  Cureus       Date:  2020-06-23

8.  Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment.

Authors:  Hamzah Abu-Sbeih; Cynthia Nguyen Tran; Phillip S Ge; Manoop S Bhutani; Mazen Alasadi; Aung Naing; Amir A Jazaeri; Yinghong Wang
Journal:  J Immunother Cancer       Date:  2019-05-03       Impact factor: 13.751

9.  A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy.

Authors:  Yuya Hirasawa; Kiyoshi Yoshimura; Hiroto Matsui; Yutaro Kubota; Hiroo Ishida; Jun Arai; Masashi Sakaki; Nao Oguro; Midori Shida; Makoto Taniguchi; Kazuyuki Hamada; Hirotsugu Ariizumi; Tomoyuki Ishiguro; Ryotaro Ohkuma; Takehiko Sambe; Atsushi Horiike; Chiyo K Imamura; Eisuke Shiozawa; Satoshi Wada; Junji Tsurutani; Sanju Iwamoto; Naoki Uchida; Yuji Kiuchi; Genshu Tate; Shinichi Kobayashi; Takuya Tsunoda
Journal:  Medicine (Baltimore)       Date:  2021-06-11       Impact factor: 1.817
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.